NIAID Continues Development of Bolder BioTechnology's BBT-059 for Acute Radiation Syndrome

Boulder, Colo., Nov. 18, 2024 – Bolder BioTechnology, Inc. announced today that the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the National Institutes of Health, has opted to fund the second year of Contract NIH-BAA-75N93023C00011. This contract is focused on the advanced development of BBT-059 to be used as a countermeasure for radiation exposure, allowing for dosing up to 48 hours post-exposure. The primary objectives of this two-year contract include completing Good Manufacturing Practice (GMP) manufacturing, preclinical safety studies, and other essential activities needed to submit an Investigational New Drug Application (IND) to the United States Food and Drug Administration. This step will enable the initiation of human testing of BBT-059. The total value of the contract amounts to $3,079,369, and its full receipt depends on meeting specific technical and business milestones.

Acute Radiation Syndrome (ARS) is a set of severe health issues that arise after high doses of ionizing radiation exposure within a short timeframe. Such exposure can occur due to incidents at nuclear power plants or the detonation of nuclear weapons. Bone marrow, responsible for creating most new blood cells, is highly sensitive to radiation. Individuals exposed to high radiation levels often suffer from bone marrow aplasia and severe neutropenia (low neutrophil count) and thrombocytopenia (low platelet count) within days to weeks post-exposure. During this period, many succumb to infections due to a lack of neutrophils or to uncontrolled bleeding due to a lack of platelets. BBT-059 has demonstrated the ability to promote bone marrow regeneration, speed up the recovery of platelets and neutrophils, and enhance survival rates in preclinical ARS models.

Bolder BioTechnology, Inc. is a clinical-stage company that leverages advanced protein engineering and bioconjugation technologies to develop safer, easier-to-use, and more effective protein therapeutics for treating human diseases.

The information provided in this press release is solely the responsibility of Bolder BioTechnology and does not necessarily reflect the official views of NIH or NIAID.